Attitude of Ophthalmologists to Transscleral Diode Laser Cyclophotocoagulation Treatment for Glaucoma Before and After Training
Abstract
Transscleral diode laser cyclophotocoagulation as treatment for glaucoma is effective in controlling IOP and preserving vision.1 Scaling up of the treatment by training has the potential to change attitudes among ophthalmologists as a viable option not just for painful blind eyes but also seeing eye,2 even as primary treatment.3 This has the potential to avoid needless blindness from poor adherence to treatment and reduced acceptance of glaucoma surgery.4 The purpose of this study was to assess the change in attitudes of ophthalmologists to transscleral diode laser cyclophotocoagulation treatment for glaucoma before and after training.
References
Kyari F, Abdull MM, Wormald R, Evans JR, Nolan W, Murthy GVS, et al. Risk factors for openangle glaucoma in Nigeria: results from the
Nigeria National Blindness and Visual Impairment Survey. BMC Ophthalmol. 2016; 16: 78.
Rotchford A P, Jayasawal R, Madhusudhan S, Ho S, King A J, Vernon S A. Transscleral diode laser cycloablation in patients with good vision.
Br. J. Ophthalmol. 2010; 94(9): 1180–1183
Egbert PRMD, Fiadoyor SMD, Budenz DLMD, Dadzie PRN, Byrd SMD. Diode Laser Transscleral Cyclophotocoagulation as a Primary Surgical Treatment for Primary Openangle Glaucoma. Arch. Ophthalmol. 2001; 119(3): 345–350.
Abdull MM, Gilbert CC, Evans J. Primary open angle glaucoma in northern Nigeria: stage at presentation and acceptance of treatment. BMC
Ophthalmol. 2015; 15(1):
